Manish Aghi, MD, PhD, MAS

Principal Investigator, Brain Tumor Research Center
Member, Helen Diller Family Comprehensive Cancer Center
Associate Professor
Department of Neurosurgery
Research Description: 

Manish Aghi is a neurosurgeon and scientist at University of California, San Francisco (UCSF). He completed his MD-PhD degrees through the MSTP program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. He is currently faculty in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. His clinical practice is focused on the surgical management of brain and skull base tumors, with special emphasis on intraoperative brain mapping for glioma surgery, pituitary tumor surgery, and minimally invasive endoscopic skull base surgery. Work in the Aghi laboratory has been funded by NIH and private foundations since 2008 and is focused on the role of tumor-microenvironment interactions in driving aggressive biology and therapeutic resistance in benign and malignant brain tumors like pituitary adenomas and gliomas. Active areas of research include the role of tumor-associated macrophages in glioblastoma growth, whole genome sequencing of pituitary adenomas, metabolic changes occurring after anti-angiogenic therapy in glioblastoma, and the role of a tyrosine kinase-integrin receptor complex in driving invasive resistance in glioblastoma. He serves as PI on multiple industry sponsored and investigator-initiated phase I-II clinical trials comparing immunotherapy versus anti-angiogenic theray of recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy to recurrent glioblastoma.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Vascular & Cardiac Biology
Research Summary: 
Defining the interaction between tumor cells and the microenvironment in glioblastoma, including during therapeutic resistance

Websites

Publications: 

Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases.

Journal of neurosurgery

Garcia JH, Morshed RA, Chung J, Millares Chavez MA, Sudhakar V, Saggi S, Avalos LN, Gallagher A, Young JS, Daras M, McDermott MW, Garcia PA, Chang EF, Aghi MK

Pituitary adenoma in the elderly: surgical outcomes and treatment trends in the United States.

Journal of neurosurgery

Chalif EJ, Morshed RA, Young JS, Haddad AF, Jain S, Aghi MK

Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.

Neuro-oncology

Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA

Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy.

World neurosurgery

Morshed RA, Chung JE, Cummins DD, Sudhakar V, Young JS, Daras M, Hervey-Jumper SL, Theodosopoulos PV, Aghi MK